Randomized Trialhigh evidence
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England)·July 30, 2026·PMID 42532079
Why it mattersZenagamtide is a first-in-class oral unimolecular agonist combining GLP-1 and amylin agonism, offering a novel mechanism for glycemic control and potential weight loss in type 2 diabetes. Its oral formulation and dual receptor activity could address unmet needs in metabolic therapeutics, providing an alternative to injectable multi-agonists.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled